FMC-R regimen
|
WikiDoc Resources for FMC-R regimen |
|
Articles |
|---|
|
Most recent articles on FMC-R regimen Most cited articles on FMC-R regimen |
|
Media |
|
Powerpoint slides on FMC-R regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on FMC-R regimen at Clinical Trials.gov Trial results on FMC-R regimen Clinical Trials on FMC-R regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on FMC-R regimen NICE Guidance on FMC-R regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on FMC-R regimen Discussion groups on FMC-R regimen Patient Handouts on FMC-R regimen Directions to Hospitals Treating FMC-R regimen Risk calculators and risk factors for FMC-R regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for FMC-R regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:R-FMC regimen;FCM-R regimen
Overview
FMC-R regimen refers to a regimen consisting of fludarabine, mitoxantrone, cyclophosphamide and rituximab, used in the treatment of resistant or relapsed chronic lymphocytic leukaemia.[1]
Regimen
FFludarabine
MMitoxantrone
CCyclophosphamide
RRituximab
Indications
References
- ↑ 1.0 1.1 Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B; et al. (2004). "The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group". Blood. 104 (10): 3064–71. doi:10.1182/blood-2004-04-1323. PMID 15284112.